We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HPHTF:OTCHamamatsu Photonics Analysis

Data as of 2026-03-12 - not real-time

$11.50

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Hamamatsu Photonics is trading at $11.5, just above the 20‑day SMA (12.09) and comfortably above the 50‑day SMA (11.46), confirming a short‑term bullish alignment. The MACD line sits at 0.36 above its signal (0.31) and the histogram is positive, reinforcing momentum, while the RSI of 75.9 flags an overbought condition that could prompt a corrective pull‑back. Price sits near the calculated support of $11.07 and faces resistance around $12.74, with volume trending downward and 30‑day volatility soaring above 50%, suggesting heightened price swings. Recent material news notes progress on a share‑buyback program, which may provide additional price support if execution proceeds as announced.
Fundamentally, the company posted modest revenue growth of 2.6% and maintains a solid gross margin of 47%, but operating and net margins are thin (4.6% and 6%). A trailing P/E of 38.3 exceeds the industry average of 34.6, indicating a premium valuation. The dividend yield of 1.94% comes with an 80% payout ratio, and a debt‑to‑equity ratio near 30 raises questions about cash flow sustainability despite a large cash balance. These fundamentals temper the bullish technical picture and suggest caution for longer‑term investors.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD crossover and SMA alignment
  • Support level just below current price
  • Share‑buyback progress signaling potential demand

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Elevated P/E relative to peers
  • High debt‑to‑equity ratio limiting financial flexibility
  • Decreasing volume and high volatility indicating uncertainty

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • Overvalued price versus industry averages
  • Weak operating margins and cash flow constraints
  • Potential dividend sustainability concerns due to high payout and debt load

Key Metrics & Analysis

Financial Health

Revenue Growth2.60%
Profit Margin6.00%
P/E Ratio38.3
ROE4.12%
ROA1.93%
Debt/Equity29.85
P/B Ratio1.7
Industry P/E34.6

Technical Analysis

TrendBullish
RSI75.9
Support$11.07
Resistance$12.74
MA 20$12.09
MA 50$11.46
MA 200$11.33
MACDBullish
VolumeDecreasing
Fear & Greed Index76.18

Valuation

GradeOvervalued
TypeBlend
Dividend Yield1.94%

Risk Assessment

Beta0.46
Volatility52.10%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.